The ESTIMATE results showed that CRC patients with high expression of SLC25A39 had lower immune score, lower stromal score, estimate score, and significantly higher tumor purity, than those in patients with low expression of SLC25A39 (P<0.001, Fig.7A). This evidence concerns the gene SLC25A39 and colorectal carcinoma.